Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.49 |
| ▸ | BRD1 | O95696 | 1/20 | 0.42 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.42 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.42 |
| ▸ | BRPF3 | Q9ULD4 | 1/20 | 0.42 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23666045 | 0.86 | AR (0.46) | ARBRD1BRPF1BRD9BRPF3 | |
| SCHEMBL523615 | 0.85 | AR (0.49) | ARBRD1BRPF1BRD9BRPF3 | |
| SCHEMBL19117523 | 0.84 | ICMT (0.46) | ARTRPV4DHFRMEN1KMT2A | |
| SCHEMBL1793475 | 0.84 | AR (0.47) | ARTRPV4CYP11B2EGLN2CYP11B1 | |
| SCHEMBL22796911 | 0.83 | AR (0.44) | ARBRD1BRPF1BRD9BRPF3 | |
| SCHEMBL16959299 | 0.81 | GAA (0.40) | ARPOLBGAAGFERMEN1 | |
| SCHEMBL14539394 | 0.81 | AR (0.45) | ARTRPV4GAACYP11B2EGLN2 | |
| SCHEMBL22796684 | 0.80 | AR (0.42) | ARBRD1BRPF1BRD9BRPF3 | |
| SCHEMBL13377029 | 0.78 | CYP2A6 (0.41) | TRPV4PTGDR2IMPDH2IMPDH1ALDH1A1 | |
| SCHEMBL509522 | 0.78 | AR (0.66) | ARCYP11B2EGLN2CYP11B1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030904-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230381335-A1 | LUNG CANCER COMBINATION THERAPY WITH IL-2 CONJUGATES AND AN ANTI-PD-1 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF | SYNTHORX INC (US) | 2023-11-30 | — | — | US | disclosed |
| WO-2023192348-A1 | CONFORMATIONALLY GATED OPTOELECTRONIC MOLECULAR RECTIFIERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023109968-A2 | SYNTHESIS METHOD FOR FINERENONE AND INTERMEDIATE THEREOF | 上海鼎雅药物化学科技有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-2022136914-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LIMITED (GB) | 2022-06-30 | — | — | WO | disclosed |
| US-20220016252-A1 | IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND ANTI-EGFR ANTIBODIES | Synthorx, Inc. (US) | 2022-01-20 | — | — | US | disclosed |
| US-20210222147-A1 | INCORPORATION OF UNNATURAL NUCLEOTIDES AND METHODS THEREOF | SANOFI (FR) | 2021-07-22 | — | — | US | disclosed |
| US-20210188860-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | Grünenthal GmbH (DE) | 2021-06-24 | — | — | US | disclosed |
| US-20210032256-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | Grünenthal GmbH (DE) | 2021-02-04 | — | — | US | disclosed |
| US-20200392550-A1 | REAGENTS AND METHODS FOR REPLICATION, TRANSCRIPTION, AND TRANSLATION IN SEMI-SYNTHETIC ORGANISMS | THE SCRIPPS RESEARCH INSTITUTE | 2020-12-17 | — | — | US | disclosed |
| US-10807988-B2 | 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | Grünenthal GmbH (DE) | 2020-10-20 | — | — | US | disclosed |
| US-20200040027-A1 | A METHOD FOR THE SITE-SPECIFIC ENZYMATIC LABELLING OF NUCLEIC ACIDS IN VITRO BY INCORPORATION OF UNNATURAL NUCLEOTIDES | THE SCRIPPS RESEARCH INSTITUTE | 2020-02-06 | — | — | US | disclosed |
| US-20190106429-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2019-04-11 | — | — | US | disclosed |
| US-10040759-B2 | Substituted azetidinyl compounds as GlyT1 inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-08-07 | — | — | US | disclosed |
| US-20180201616-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2018-07-19 | — | — | US | disclosed |
| US-20170334846-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-11-23 | — | — | US | disclosed |
| US-20170197970-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | GRUENENTHAL GMBH (DE) | 2017-07-13 | — | — | US | disclosed |
| EP-1979314-B1 | INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS | LILLY CO ELI (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-7226950-B2 | Sodium channel modulators | THERAVANCE, INC. (US) | 2007-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | AR 558/4885BRD1 1373/4885BRPF1 2350/4885 |
| US-20210032256-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | AR 274/4885BRD1 1013/4885BRPF1 3385/4885 |
| US-20220016252-A1 | IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND ANTI-EGFR ANTIBODIES | IL2, IL2RA, EGFR | AR 938/4885BRD1 3667/4885BRPF1 4048/4885 |
| US-20170197970-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | AR 274/4885BRD1 1013/4885BRPF1 3385/4885 |
| US-12030904-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | AR 4609/4885BRD1 3387/4885BRPF1 1490/4885 |
| US-20180201616-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | AR 274/4885BRD1 1013/4885BRPF1 3385/4885 |
| US-10040759-B2 | Substituted azetidinyl compounds as GlyT1 inhibitors | GLRA1, AGXT, B4GALT1 | AR 2083/4885BRD1 1559/4885BRPF1 1545/4885 |
| US-10807988-B2 | 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | OPRK1, OPRD1, OPRL1 | AR 274/4885BRD1 1013/4885BRPF1 3385/4885 |
| US-20200040027-A1 | A METHOD FOR THE SITE-SPECIFIC ENZYMATIC LABELLING OF NUCLEIC ACIDS IN VITRO BY INCORPORATION OF UNNATURAL NUCLEOTIDES | RNGTT, POLM, POLRMT | AR 3211/4885BRD1 2766/4885BRPF1 1885/4885 |
| US-20170334846-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | GLRA1, AGXT, B4GALT1 | AR 2083/4885BRD1 1559/4885BRPF1 1545/4885 |
| US-20200392550-A1 | REAGENTS AND METHODS FOR REPLICATION, TRANSCRIPTION, AND TRANSLATION IN SEMI-SYNTHETIC ORGANISMS | RNGTT, MAX, POLRMT | AR 3475/4885BRD1 2516/4885BRPF1 1411/4885 |
| US-20230381335-A1 | LUNG CANCER COMBINATION THERAPY WITH IL-2 CONJUGATES AND AN ANTI-PD-1 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF | IL2, PDCD1LG2, CD274 | AR 2249/4885BRD1 1701/4885BRPF1 2664/4885 |
| US-20210188860-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | AR 274/4885BRD1 1013/4885BRPF1 3385/4885 |
| US-20190106429-A1 | 3-((Hetero-)Aryl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, OPRL1 | AR 274/4885BRD1 1013/4885BRPF1 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.